In a prelude to what is hoped will be regulatory approval of MDMA-assisted therapy in the U.S. and Canada, Numinus Wellness Inc. (OTC: NUMIF) has taken steps to get out in front of the curve.
Numinus has submitted a Clinical Trial Application (CTA) to Health Canada to enable MDMA-assisted therapy Experiential Opportunities for practitioners as part.
The company was selected to manufacture and supply MDMA for the program set to take place later this year, pending clinical trial approvalVANCOUVER, British Columbia, June 15, 2023 Optimi Health. | June 15, 2023
VANCOUVER, British Columbia, June 15, 2023 (GLOBE NEWSWIRE) Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), an end-to-end drug researcher and formulator licensed by Health Canada